HRP20040385A2 - Pharmaceutical composition comprising an adenosine a1/a2 agonist and a sodium hydrogen exchanger inhibitor - Google Patents

Pharmaceutical composition comprising an adenosine a1/a2 agonist and a sodium hydrogen exchanger inhibitor

Info

Publication number: HRP20040385A2
Authority: HR; Croatia
Prior art keywords: sub; adenosine; agonist; pharmaceutical composition; sodium hydrogen
Prior art date: 2001-11-02

Application number

HR20040385A

Other languages

English (en)

Inventor

M. Downey James

Xu Zhelong

Shukla Umesh

Original Assignee

Aventis Pharmaceuticals Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-02

Filing date

2002-11-01

Publication date

2005-06-30

2002-02-15 Priority claimed from GB0203596A external-priority patent/GB0203596D0/en

2002-11-01 Application filed by Aventis Pharmaceuticals Inc. filed Critical Aventis Pharmaceuticals Inc.

2005-06-30 Publication of HRP20040385A2 publication Critical patent/HRP20040385A2/xx

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

HR20040385A 2001-11-02 2002-11-01 Pharmaceutical composition comprising an adenosine a1/a2 agonist and a sodium hydrogen exchanger inhibitor HRP20040385A2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US33631501P	2001-11-02	2001-11-02
GB0203596A GB0203596D0 (en)	2002-02-15	2002-02-15	Pharmaceutical composition comprising of adenosine A1/A2 agonist and a sodium hydrogen exchanger inhibitor
PCT/US2002/035096 WO2003039528A1 (fr)	2001-11-02	2002-11-01	Composition pharmaceutique comprenant un agoniste d'adenosine a1/a2 et un inhibiteur d'echangeur sodium-hydrogene

Publications (1)

Publication Number	Publication Date
HRP20040385A2 true HRP20040385A2 (en)	2005-06-30

Family

ID=26246972

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20040385A HRP20040385A2 (en)	2001-11-02	2002-11-01	Pharmaceutical composition comprising an adenosine a<sub>1</sub>/a<sub>2</sub> agonist and a sodium hydrogen exchanger inhibitor

Country Status (16)

Country	Link
US (1)	US20040248928A1 (fr)
EP (1)	EP1443916A1 (fr)
JP (1)	JP2005511590A (fr)
KR (1)	KR20050042225A (fr)
CN (1)	CN1585634A (fr)
BR (1)	BR0213820A (fr)
CA (1)	CA2465364A1 (fr)
HR (1)	HRP20040385A2 (fr)
HU (1)	HUP0401853A2 (fr)
IL (1)	IL161676A0 (fr)
MA (1)	MA27073A1 (fr)
MX (1)	MXPA04003124A (fr)
NO (1)	NO20042142L (fr)
PL (1)	PL369074A1 (fr)
RU (1)	RU2004116686A (fr)
WO (1)	WO2003039528A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20060272A1 (es)	2004-05-24	2006-05-22	Glaxo Group Ltd	(2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
GB0514809D0 (en)	2005-07-19	2005-08-24	Glaxo Group Ltd	Compounds
JP4664797B2 (ja) *	2005-10-13	2011-04-06	ジーイー・メディカル・システムズ・グローバル・テクノロジー・カンパニー・エルエルシー	Ｍｒｉ装置

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
YU46200A (sh) *	1998-02-27	2003-02-28	Pfizer Products Inc.	N-(supstituisani peto-članog di-ili triaza dinezasićenog prstena)karbonil/guanidin derivati za tretiranje ishemije
CO5180581A1 (es) *	1999-09-30	2002-07-30	Pfizer Prod Inc	Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia

2002
- 2002-11-01 WO PCT/US2002/035096 patent/WO2003039528A1/fr not_active Ceased
- 2002-11-01 RU RU2004116686/15A patent/RU2004116686A/ru not_active Application Discontinuation
- 2002-11-01 CN CNA028214226A patent/CN1585634A/zh active Pending
- 2002-11-01 BR BR0213820-4A patent/BR0213820A/pt not_active IP Right Cessation
- 2002-11-01 IL IL16167602A patent/IL161676A0/xx unknown
- 2002-11-01 CA CA002465364A patent/CA2465364A1/fr not_active Abandoned
- 2002-11-01 HR HR20040385A patent/HRP20040385A2/xx not_active Application Discontinuation
- 2002-11-01 EP EP02786638A patent/EP1443916A1/fr not_active Withdrawn
- 2002-11-01 HU HU0401853A patent/HUP0401853A2/hu unknown
- 2002-11-01 JP JP2003541819A patent/JP2005511590A/ja active Pending
- 2002-11-01 MX MXPA04003124A patent/MXPA04003124A/es not_active Application Discontinuation
- 2002-11-01 PL PL02369074A patent/PL369074A1/xx not_active Application Discontinuation
- 2002-11-01 KR KR1020047006625A patent/KR20050042225A/ko not_active Withdrawn
2004
- 2004-04-06 MA MA27610A patent/MA27073A1/fr unknown
- 2004-04-30 US US10/835,964 patent/US20040248928A1/en not_active Abandoned
- 2004-05-25 NO NO20042142A patent/NO20042142L/no unknown

Also Published As

Publication number	Publication date
WO2003039528A1 (fr)	2003-05-15
RU2004116686A (ru)	2005-03-27
NO20042142L (no)	2004-05-25
US20040248928A1 (en)	2004-12-09
CA2465364A1 (fr)	2003-05-15
KR20050042225A (ko)	2005-05-06
MA27073A1 (fr)	2004-12-20
MXPA04003124A (es)	2004-11-29
CN1585634A (zh)	2005-02-23
BR0213820A (pt)	2004-08-31
IL161676A0 (en)	2004-09-27
HUP0401853A2 (hu)	2004-12-28
EP1443916A1 (fr)	2004-08-11
JP2005511590A (ja)	2005-04-28
PL369074A1 (en)	2005-04-18

Similar Documents

Publication	Publication Date	Title
HUP0203965A3 (en)	2003-07-28	Indazole compounds and pharmaceutical compositions containing them
IL181356A0 (en)	2007-07-04	Tamper-resistant oral opioid agonist formulations
HUP0303325A3 (en)	2008-03-28	Pharmaceutical salts and pharmaceutical compositions containing them
HUP0303197A3 (en)	2008-03-28	Compositions containing alpha-2 adrenergic agonist components
HUS1400025I1 (hu)	2016-08-29	Feniletanolamin-származékok és az ezeket tartalmazó gyógyszerek
GB2353523B (en)	2004-03-17	Methods and compositions for use in cementing in cold environments
HUP0303108A3 (en)	2012-10-29	Substituted pyrazoles and pharmaceutical compositions containing them
IL209444A0 (en)	2011-07-31	O-desmethyl-venlafaxine succinate salts and pharmaceutical compositions containing them
AU2001284564A1 (en)	2002-03-13	Nucleoside metabolism inhibitors
AU2002239991A1 (en)	2002-07-30	Electronic procurement ("e-procurement")
HUP0400328A3 (en)	2007-05-29	Metalloproteinase inhibitor azoles and pharmaceutical compositions containing them
HUP0300409A3 (en)	2003-09-29	Pharmaceutical compositions containing antiadhesive carbohydrates and their use
IL205407A0 (en)	2011-07-31	Hyaluronic acid antagonist and inhibitor compositions and uses thereof
AU2002220241A1 (en)	2002-06-11	Parb inhibitors
EG24194A (en)	2008-10-14	5ht-a-partial agonist pharmaceutical compositions
HUP0302160A3 (en)	2005-05-30	Pharmaceutical compositions containing the combination of gaba agonists and sorbitol dehydrogenase inhibitors
IL158236A0 (en)	2004-05-12	Pharmaceutical compositions containing azithromycin and derivatives thereof
HUP0400654A3 (en)	2011-07-28	Substituted 8-arylquinoline phosphodiesterase 4 inhibitors and pharmaceutical compositions containing them
HUP9801924A3 (en)	2004-11-29	Combination containing sodium/hydrogen exchange inhibitors
HUP0401504A3 (en)	2008-05-28	Substituted azole karboxylic acid derivatives useful as antidiabetic and antiobesity agents and pharmaceutical compositions containing them
AU8186101A (en)	2002-01-02	1-amino-alkylcyclohexanes as 5-HT<sub>3</sub> and neuronal nicotinicreceptor antagonists
PL342763A1 (en)	2001-07-02	Matrix metaloprotease inhibitor
HUP0303533A3 (en)	2005-02-28	Adenosine a1 agonist adenosine derivatives
AU1202601A (en)	2001-04-30	All-organic corrosion inhibitor composition and uses thereof
AU2003293635A8 (en)	2004-05-25	4'' - modified erythromycin derivatives

Legal Events

Date	Code	Title	Description
2005-06-30	A1OB	Publication of a patent application
2005-10-19	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20051019 Year of fee payment: 4
2005-12-21	ARAI	Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
2008-11-05	OBST	Application withdrawn

HRP20040385A2 - Pharmaceutical composition comprising an adenosine a<sub>1</sub>/a<sub>2</sub> agonist and a sodium hydrogen exchanger inhibitor - Google Patents